Establishment of Banking System for Allogeneic Cultured Dermal Substitute

Artificial Organs

Volumn 28, Issue 1, 2004, Pages 13-21

  Kuroyanagi, Yoshimitsu ^a,b   Kubo, Kentaro ^a   Matsui, Hiromich ^a   Kim, Hyun Jung ^a   Numari, Shinichiro ^a   Mabuchi, Yho ^a   Kagawa, Shizuko ^a  

^a KITASATO UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Cell growth factor; Collagen; Cultured dermal substitute; Fibroblasts; Hyaluronic acid; Tissue engineering

Indexed keywords

ARTIFICIAL ORGANS; CELL CULTURE; CELL ENGINEERING; CLINICAL RESEARCH; COLLAGEN; ENDOTHELIAL CELLS; HYALURONIC ACID; ORGANIC ACIDS; TISSUE; TISSUE ENGINEERING;

BASIC FIBROBLAST GROWTH FACTOR; CELL GROWTH FACTOR; CRYOPRESERVED; CULTURE MEDIUM; CULTURED DERMAL SUBSTITUTES; CYTOKINES; HEPATOCYTE GROWTH FACTOR; MATRIX; TISSUES ENGINEERINGS; VASCULAR ENDOTHELIAL GROWTH FACTOR;

FIBROBLASTS;

ATELOCOLLAGEN; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR; HYALURONIC ACID; INTERLEUKIN 6; INTERLEUKIN 8; KERATINOCYTE GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR AA; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ALLOTRANSPLANTATION; ARTICLE; ARTIFICIAL SKIN; BURN; CELL PROLIFERATION; CELL STIMULATION; CLINICAL RESEARCH; CRYOPRESERVATION; CULTURE MEDIUM; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST CULTURE; HOSPITAL; HUMAN; JAPAN; KERATINOCYTE; PRIORITY JOURNAL; SKIN ALLOGRAFT; SKIN FIBROBLAST; SKIN ULCER; THAWING; TISSUE ENGINEERING; WOUND HEALING;

EID: 1242342182     PISSN: 0160564X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1594.2004.07318.x     Document Type: Article

References (66)

1. Rheinwald JG, Green H. Serial cultivation of strains of human epidermal keratinocytes: The formation of keratinizing colonies from single cells. Cell 1975;6:331-43.
2. Green H, Kehinde O, Thomas J. Growth of cultured human epidermal cells into multiple epithelia suitable for grafting. Proc Natl Acad Sci USA 1979;76:5665-8.
3. O'Connor NE, Muliken JG, Banks-Schlegel S, Kehinde O, Green H. Grafting of burns with cultured epithelium prepared from autologous epidermal cells. Lancet 1981;1:75-8.
4. Gallico G, O'Connor NE, Compton CC, Kehinde O, Green H. Permanent coverage of large burn wounds with autologous cultured human epithelium. N Engl J Med 1984;311:448-51.
5. Compton CC, Gill JM, Bradford DA, Regauer S, Gallico GG, O'Connor NE. Skin regenerated from cultured epithelial autografts on full-thickness burn wounds from 6 days to 5 years after grafting. Lab Invest 1989;60:600-12.
6. Cooper ML, Hansbrough JF, Spielvogel RL, Cohen R, Bartel RL, Naughton G. In vivo optimization of a living dermal substitute employing cultured human fibroblasts on a biodegradable polyglycolic acid or polyglactin mesh. Biomaterials 1991; 12:243-8.
7. Hansbrough JF, Christine D, Hansbrough WB. Clinical trials of a living dermal tissue replacement placed beneath meshed, split-thickness skin grafts on excised burn wounds. J Burn Care Rehabil 1992;13:519-29.
8. Hansbrough JF, Cooper ML, Cohen R, Spielvogel R, Greenleaf G, Bartel RL, Naughton G. Evaluation of a biodegradable matrix containing cultured human fibroblasts as a dermal replacement beneath meshed skin grafts on athymic mice. Surgery 1992;111:438-46.
9. Gentzkow GD, Iwasaki SD, Hershon KS, et al. Use of dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care 1996;19:350-4.
10. Hansbrough JF, Mozingo DW, Kealey GP, Davis M, Gidner A, Gentzkow GD. Clinical trials of a biosynthetic temporary skin replacement, Dermagraft-Transitional Covering, compared with cryopreserved human cadaver skin for temporary coverage of excised burn wounds. J Burn Care Rehabil 1997;18:43-51.
11. Hansbrough JF, Morgan J, Greenleaf G. Development of a temporary living skin replacement composed of human neonatal fibroblasts cultured in Biobrane, a synthetic dressing material. Surgery 1994;115:633-44.
12. Bell E, Ivarsson B, Merrill C. Production of a tissue-like structure by contraction of collagen lattices by human fibroblasts of different proliferative potential in vitro. Proc Natl Acad Sci USA 1979;211:1274-48.
13. Bell E, Ehrlich HP, Buttle DJ, Nakatsuji T. Living tissue formed in vitro and accepted as skin-equivalent tissue of full thickness. Science 1981;211:1052-4.
14. Bell E, Ehrlich HP, Sher S, et al. Development and use of a living skin equivalent. Plast Reconstr Surg 1981;67:386-92.
15. Bell E, Sher S, Hull B, et al. The reconstitution of living skin. J Invest Dermatol 1983;81:S2-10.
16. Naughton G. The Advanced Tissue Sciences story. Sci Am 1999;280:84-5.
17. Yamada N, Shioya N, Kuroyanagi Y. Evaluation of an allogeneic cultured dermal substitute composed of fibroblasts within a spongy collagen matrix as a wound dressing. Scand J Plast Reconstr Surg 1995;29:211-19.
18. Tanaka M, Nakakita N, Kuroyanagi Y. Allogeneic cultured dermal substitute composed of spongy collagen containing fibroblasts: Evaluation in animal test. J Biomater Sci Polymer Edn 1999;10:433-53.
19. Yamada N, Uchinuma N, Kuroyanagi Y. Clinical evaluation of an allogeneic cultured dermal substitute composed of fibroblasts within a spongy collagen matrix. Scand J Plast Reconstr Surg 1999;33:147-54.
20. Kuroyanagi Y, Yamada N, Yamashita R, Uchinuma E. Tissue-engineered product: allogeneic cultured dermal substitute composed of spongy collagen with fibroblasts. Artif Organs 2001;25:180-6.
21. Kubo K, Kuroyanagi Y. Development of cultured dermal substitute composed of spongy matrix of hyaluronic acid and atelo-collagen combined with fibroblasts: Fundamental evaluation. J Artif Organs 2003;6:64-70.
22. Kubo K, Kuroyanagi Y. Characterization of cultured dermal substitute composed of spongy matrix of hyaluronic acid and collagen combined with fibroblasts. J Artif Organs 2003;6:138-44.
23. Kubo K, Kuroyanagi Y. Development of cultured dermal substitute composed of spongy matrix of hyaluronic acid and atelo-collagen combined with fibroblasts: Fundamental evaluation. J Biomater Sci Polymer Edn 2003;14:625-41.
24. Kubo K, Kuroyanagi Y. Development of cultured dermal substitute composed of spongy matrix of hyaluronic acid and atelo-collagen combined with fibroblasts; Cryopreservation. Artif Organs 2004;28 (in press).
25. Kubo K, Kuroyanagi Y. Effects of VEGF released from cultured dermal substitute on proliferation of vascular endothelial cells in vitro. J Artif Organs (in press).
26. Benedetti L, Cortivo R, Berti T, et al. Biocompatibility and biodegradation of different hyaluronan derivatives (Hyaff) implanted in rats. Biomaterials 1993;14:1154-60.
27. Postlethwaite AE, Seyer JM, Kang AH. Chemotactic attraction of human fibroblasts to type I, II, and III collagens and collagen-derived peptides. Proc Natl Acad Sci USA 1978;75: 871-5.
28. Kuroyanagi Y, Kubo K, Matsui H, Kagawa S, Mori S, Kim H-J, Mabuchi Y. Manufacturing and banking system for allogeneic cultured dermal substitute. Jpn J Burn Injuries 2003;29:28-38.
29. Oka H, Fujitsu M, Suenobu K, et al. Clinical trials with allogeneic cultured dermal substitute (CDS) for the treatment of burns and skin ulcers. Jpn J Burn Injuries 2002;28:333-42.
30. Harima N, Ansai S, Wako M, et al. Clinical trials using allogeneic cultured dermal substitutes for skin ulcers. Jpn J Dermatol 2003;113:253-64.
31. Kubo K, Kuroyanagi Y. A study of cytokines released from fibroblasts in cultured dermal substitute (CDS). Tissue Eng (in submission).
32. Ono I, Gunji H, Suda K, Iwatsuki K, Kaneko F. Evaluation of cytokines in donor site wound fluids. Scand J Plast Reconstr Surg Hand Surg 1994;28:269-73.
33. Ono I, Gunji H, Suda K, Zhang JZ, Maruyama K, Kaneko F. A study of cytokines in burn blister fluid related to wound healing. Burns 1995;21:352-5.
34. Falanga V, Grinnel F, Gilchrest B, Maddox YT, Moshell A. Experimental approaches to chronic wounds. Wound Rep Reg 1995;3:132-40.
35. Yager DR, Zhang LY, Liang HX, Diegelmann RF, Cohen IK. Wound fluids from human pressure ulcers contain elevated matrix metalloproteinase levels and activity compared to surgical wound fluids. J Invest Dermatol 1996;107:743-8.
36. Yager DR, Chen SM, Ward SI, Olutoye OO, Diegelmann RF, Cohen IK. Ability of chronic wound fluids to degrade peptide growth factors is associated with increased levels of elastase activity and diminished levels of proteinase inhibitors. Wound Rep Reg 1997;5:23-32.
37. Weckroch M, Vaheri A, Lauharanta J, Sorsa T, Konttinen YT. Matrix metalloproteinases, gelatinase, and collagenase in chronic leg ulcers. J Invest Dermatol 1996;109:1119-24.
38. Wysocki AB, Staiano-Coico L, Grinnel F. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinase MMP-2 and MMP-9. J Invest Dermatol 1993;101: 64-8.
39. Hehenger K, Heliborn J, Brismar K, Hansson A. Inhibited proliferation of fibroblasts derived from chronic diabetic wounds and normal dermal fibroblasts treated with high glucose is associated with increased formation of 1-lactate. Wound Rep Reg 1998;6:135-41.
40. Hehenger K, Kratz GK, Hansson A, Brismar K. Fibroblasts derived from human chronic diabetic wounds have a decreased proliferation rate, which is recovered by the addition of heparin. J Dermatol Sci 1998;16:144-51.
41. Stanley AC, Park HY, Phillips TJ, Russakovsky V, Menzoian JO. Reduced growth of dermal fibroblasts from chronic venous ulcers can be stimulated with growth factors. J Vasc Surg 1997;26:994-1001.
42. LeGrand EK. Preclinical promise of Becaplermin (rhPDGF-BB) in wound healing. Am J Surg 1998;176:48-54.
43. Mustoe TA, Pierce GF, Morishima C, Deuel TF. Growth factor-induced acceleration of tissue repair through direct and inductive activities in a rabbit dermal ulcer model. J Clin Invest 1991;87:694-703.
44. Greenhalgh DG, Sprugel KH, Murray MJ, Ross R. PDGF and FGF stimulate wound healing in the genetically diabetic mouse. Am J Pathol 1990;136:1235-46.
45. Robson MC, Phillips LG, Lawrence WT, et al. The safety and effect of topically applied recombinant basic fibroblast growth factor on healing of chronic pressure sores. Ann Surg 1992;216:401-8.
46. Falanga V, Eaglstein WH, Bucalo B, Kartz MH, Harris B. Carson P. Topical use of human recombinant epidermal growth factor (h-EGF) in venous ulcers. J Dermatol Surg Oncol 1992;18:604-6.
47. Corral CJ, Siddiqui A, Wu L, Farrell CL, Lyons D, Mustoe TA. Vascular endothelial growth factor is more important than basic fibroblastic growth factor during ischemic wound healing. Arch Surg 1999;134:200-5.
48. Nayeri F, Stromberg T, Larsson M, Brudin L, Soderstrom C, Forsberg P. Hepatocyte growth factor may accelerate healing in chronic leg ulcers: pilot study. J Dermatol Treat 2002;13:81-6.
49. Robson MC, Phillips LG, Cooper DM, Lyle WG. The safety and effect of transforming growth factor β for the treatment of venous stasis ulcers. Wound Rep Reg 1993;3:157-67.
50. Dijke P, Iwata KK. Growth factors for wound healing. Biotechnology 1989;7:793-8.
51. Moulin V. Growth factor in skin wound healing. Eur J Cell Blol 1995;68:1-7.
52. Postlethwaite AE, Oja JK, Moses HL, Kang AH. Stimulation of chemotactic migration of human fibroblast by TGF-β. J Exp Med 1987;165:251-6.
53. Tsuboi R, Sato C, Kurita Y, Ron D, Rubin JS, Ogawa H. KGF (FGF-7) stimulates migration and plasminogen activator activity of normal human keratinocytes. J Invest Dermatol 1993;101:49-53.
54. Nissen NN, Polverini PJ, Koch AE, Volin MV, Gamelli RL, DiPietro LA. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol 1998;152:1445-52.
55. Kumar R, Yoneda J, Fidler IJ. Regulation of distinct steps of angiogenesis by different angiogenic molecules. Int J Oncol 1998;12:749-57.
56. Toyoda M, Takayama H, Horiguchi N, et al. Overexpression of hepatocyte growth factor/scatter factor promotes vascularization and granulation tissue formation in vivo. FEBS Lett 2001;509:95-100.
57. Gillitzer R, Goebeler M. Chemokines in cutaneous wound healing. J Leukoc Biol 2001;69:513-21.
58. Li A, Dubey S, Varney ML, Dave BJ, Singh RK. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 2003;170:3369-76.
59. Clark RAF. Overview and general consideration of wound repair. In: Clark RAF, Henson PM, eds. The Molecular and Cellular Biology of Wound Repair. New York: Plenum Press, 1988;3-33.
60. Grinnel F. Wound repair, keratinocyte activation and integrin modulation. J Cell Sci 1992;101:1-5.
61. Brown GL, Nanney LB, Griffen J, et al. Enhancement of wound healing by topical treatment with epidermal growth factor. N Engl J Med 1989;321:76-9.
62. Coffey RJ, Sipes NJ, Bascom CC, GravesDeal R, Pennington CY, Weissman BE, Moses HL. Growth modulation of mouse keratinocytes by transforming growth factor. Cancer Res 1988;48:1596-604.
63. Nishida T, Nakamura M, Mishima H, Otori T. Interleukin 6 promote epithelial migration by a fibronectin-dependent mechanism. J Cell Physiol 1992;153:1-5.
64. Paquet P, Pierard GE. Interleukin-6 and the skin. Int Arch Allergy Immunol 1996;109:308-17.
65. Gailit J, Welch MP, Clark RAF. TGFβ1 stimulates expression of keratinocyte integrins during re-epithelialization of cutaneous wounds. J Invest Dermatol 1994;103:221-7.
66. Kashiwa N, Ito O, Ueda T, Kubo K, Matsui H, Kuroyanagi Y. Treatment of full-thickness skin defect with concomitant grafting of 6-fold extended mesh auto-skin and allogeneic cultured substitute. Artif Organs (in submission).